Apellis Pharmaceuticals Inc Cash Flow-to-Debt Ratio
Apellis Pharmaceuticals Inc cash flow-to-debt ratio. Apellis Pharmaceuticals Inc (APLS) has a Cash Flow-to-Debt Ratio of -0.09x as of March 2026, meaning its operating cash flow of $-60.97 Million could theoretically repay 0% of its total liabilities ($667.61 Million) in one year. Check Apellis Pharmaceuticals Inc (APLS) cash flow quality to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Apellis Pharmaceuticals Inc (2013–2025)
Cash flow-to-debt ratio of Apellis Pharmaceuticals Inc from 2013 to 2025. Historical debt coverage capacity for Apellis Pharmaceuticals Inc across 13 annual periods. Check APLS cash reinvestment to operating cash ratio to assess the company's total reinvestment commitment from operating cash flow.
Apellis Pharmaceuticals Inc Cash Flow-to-Debt Ratio by Year (2013–2025)
Apellis Pharmaceuticals Inc cash flow-to-debt ratio by year from 2013 to 2025. Year-by-year debt coverage analysis for Apellis Pharmaceuticals Inc. For the full cash flow conversion analysis, see Apellis Pharmaceuticals Inc (APLS) cash flow conversion.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 0.06x | $45.33 Million | $705.11 Million | ▲ +148.0% |
| 2024 | -0.13x | $-87.87 Million | $656.51 Million | ▲ +86.6% |
| 2023 | -1.00x | $-594.74 Million | $594.21 Million | ▼ -15.0% |
| 2022 | -0.87x | $-513.75 Million | $590.35 Million | ▼ -5.6% |
| 2021 | -0.82x | $-563.13 Million | $683.10 Million | ▼ -288.3% |
| 2020 | -0.21x | $-160.49 Million | $756.01 Million | ▲ +64.3% |
| 2019 | -0.59x | $-211.13 Million | $355.02 Million | ▲ +80.7% |
| 2018 | -3.08x | $-131.24 Million | $42.56 Million | ▼ -119.6% |
| 2017 | -1.40x | $-46.60 Million | $33.19 Million | ▲ +80.4% |
| 2016 | -7.15x | $-26.00 Million | $3.64 Million | ▼ -21.3% |
| 2015 | -5.89x | $-18.86 Million | $3.20 Million | ▲ +35.9% |
| 2014 | -9.20x | $-9.95 Million | $1.08 Million | ▼ -80.7% |
| 2013 | -5.09x | $-3.44 Million | $676.96K | — |